Neurocrine Biosciences Inc (NAS:NBIX)
$ 136.53 -0.46 (-0.34%) Market Cap: 13.82 Bil Enterprise Value: 12.85 Bil PE Ratio: 36.60 PB Ratio: 5.08 GF Score: 88/100

Neurocrine Biosciences Inc at Credit Suisse Healthcare Conference - Scottsdale Transcript

Nov 12, 2019 / 08:50PM GMT
Release Date Price: $111.4 (+0.50%)
Evan David Seigerman;dit Suisse AG
CrÃ;Research Division - VP & Senior Equity Research Analyst

© -

We're ready. Hi, there. My name is Evan Seigerman, and I'm the senior large-cap biotechnology analyst here at Crédit Suisse. And with me today, we have Neurocrine Biosciences. And representing Neurocrine, we have Matt Abernethy, the CFO. Before we get started, I think you have a few comments.

Matthew C. Abernethy
Neurocrine Biosciences, Inc. - CFO

Yes, sure. Thanks, Evan, and thank you to you and Crédit Suisse for inviting us to this year's health care conference.

Before I begin, I will be making forward-looking statements. So I would direct you to our latest SEC filings for the related risk factors and uncertainties associated with our company and then also our industry. Evan, before we jump into the Q&A, I thought it may make sense for me to just give a brief overview of who Neurocrine is for those not as familiar with our story.

So Neurocrine has been around for quite some time, over 25 years, with a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot